TCGA-B6-A1KI-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.430
- HEDGEHOG_SIGNALING+0.400
- BILE_ACID_METABOLISM+0.350
- FATTY_ACID_METABOLISM+0.310
- ESTROGEN_RESPONSE_EARLY+0.300
- PROTEIN_SECRETION+0.280
- UV_RESPONSE_DN+0.280
- TGF_BETA_SIGNALING+0.270
- ANGIOGENESIS+0.260
- MYOGENESIS+0.260
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.570
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_GAMMA_RESPONSE-0.490
- MYC_TARGETS_V1-0.480
- INTERFERON_ALPHA_RESPONSE-0.470
- MYC_TARGETS_V2-0.450
- INFLAMMATORY_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.330
- SPERMATOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613754 | — | F | 0.884 |
| 2 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.852 |
| 3 | SRR8518290 | — | F | 0.850 |
| 4 | TCGA-62-8395-01A-11R-2326-07 | — | cohortA2 | 0.844 |
| 5 | C3N-01021 | — | cohortA1 | 0.839 |
| 6 | TCGA-D8-A27P-01A-11R-A16F-07 | — | B | 0.836 |
| 7 | TCGA-CN-4722-01A-01R-1436-07 | — | — | 0.831 |
| 8 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.831 |
| 9 | 20030071.Her2HRpos | — | A | 0.827 |
| 10 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |